Compare RRGB & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRGB | JSPR |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.0M | 14.9M |
| IPO Year | 2002 | N/A |
| Metric | RRGB | JSPR |
|---|---|---|
| Price | $7.02 | $0.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $9.00 | ★ $15.50 |
| AVG Volume (30 Days) | 373.1K | ★ 500.9K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,315,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $0.32 |
| 52 Week High | $8.26 | $4.00 |
| Indicator | RRGB | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 38.25 |
| Support Level | $3.73 | $0.42 |
| Resistance Level | $7.52 | $0.60 |
| Average True Range (ATR) | 0.62 | 0.07 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 68.10 | 39.73 |
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.